<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapies that can be used to treat VWD and AVWS</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapies that can be used to treat VWD and AVWS</h1>
<div class="graphic"><div class="figure"><div class="ttl">Therapies that can be used to treat VWD and AVWS</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Dose</td> <td class="subtitle1">Comments</td> </tr> <tr> <td>DDAVP</td> <td> <ul> <li><strong>Intravenous:</strong> 0.3 mcg/kg (maximum dose, 20 mcg) in 50 mL saline over 20 minutes</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <ul> <li><strong>Nasal spray:</strong> Weight &gt;50 kg: 300 mcg (1 spray in each nostril); weight &lt;50 kg: 150 mcg (1 spray in 1 nostril)</li> </ul> </td> <td> <ul> <li>Adequate response to a test dose is ideally established before use, but a patient with AVWS and acute bleeding may receive the first dose as a therapeutic trial</li> <li>Use caution when an antifibrinolytic agent is given concurrently due to risk of thrombosis</li> <li>Dose may be repeated after 12 hours and 24 hours</li> <li>Tachyphylaxis and hyponatremia may occur; monitor hemostasis and serum sodium</li> <li>Thrombocytopenia may worsen in some type 2B patients</li> </ul> </td> </tr> <tr> <td>VWF concentrates (these contain all VWF multimers)</td> <td> <ul> <li><strong>Major bleeding or surgery:</strong> Initial dose 40 to 60 ristocetin cofactor units/kg followed by 20 to 40 ristocetin cofactor units/kg every 12 to 24 hours to keep VWF level 50 to 100 international units/dL for 7 to 14 days, or as indicated clinically</li> <li><strong>Minor bleeding or surgery:</strong> Initial dose 30 to 60 ristocetin cofactor units/kg followed by 20 to 40 ristocetin cofactor units/kg every 12 to 48 hours to keep VWF level &gt;30 international units/dL for 3 to 5 days, or less as indicated clinically</li> </ul> </td> <td> <ul> <li>Dose and duration based on clinical experience</li> <li>Case reports have described the use of continuous infusion (2 to 15 international units/kg per hour) in cases of serious bleeding that does not respond to intermittent dosing</li> <li>Increased doses or more frequent administration may be necessary in AVWS</li> </ul> </td> </tr> <tr> <td>Recombinant VWF</td> <td> <ul> <li><strong>Major bleeding or surgery:</strong> Initial dose 50 to 80 international units/kg, followed by 40 to 60 international units/kg every 8 to 24 hours to keep the VWF level 50 to 100 international units/kg for 2 to 3 days or longer, as needed clinically</li> <li><strong>Minor bleeding or surgery:</strong> Initial dose 40 to 50 international units/kg, followed by 40 to 50 international units/kg every 8 to 24 hours as needed clinically</li> </ul> </td> <td> <ul> <li>In patients with less than 40% factor VIII activity, 1 dose of recombinant factor VIII is given (dose ratio of 1 to 1.3 for rFVIII to rVWF) within 10 minutes of the first dose of rVWF</li> <li>Published studies using rVWF are limited, and more data are needed to assess responses in patients of differing ages and severities of VWD and in specific clinical settings</li> </ul> </td> </tr> <tr> <td>Antifibrinolytic agents</td> <td> <ul> <li>Aminocaproic acid, 25 to 50 mg/kg per dose orally (maximum 5 g dose) 4 times per day</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <ul> <li>Tranexamic acid, 25 mg/kg per dose orally every 6 to 8 hours or 10 mg/kg intravenously 3 times per day</li> </ul> </td> <td> <ul> <li>Can be used alone or in conjunction with other therapies; use caution when combined with DDAVP</li> <li>Especially useful for mucosal bleeding (often used for dental procedures)</li> <li>Dose reduction may be required in patients with impaired kidney function</li> </ul> </td> </tr> <tr> <td>IVIG (only applies to AVWS)</td> <td> <ul> <li>1 g/kg intravenously once daily for 2 days*</li> </ul> </td> <td> <ul> <li>May be particularly helpful in monoclonal gammopathies</li> <li>May be used in conjunction with VWF concentrates and/or DDAVP, particularly when treating AVWS associated with autoimmune disease</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Refer to UpToDate topics on the management of VWD and AVWS for additional information.</div><div class="graphic_footnotes"><p>VWD: von Willebrand disease; AVWS: acquired von Willebrand syndrome; DDAVP: desmopressin; VWF: von Willebrand factor; rFVIII: recombinant factor VIII; rVWF: recombinant VWF; IVIG: intravenous immune globulin.</p>
    
    * Divided doses may be required; refer to UpToDate topics on IVIG for details.</div><div class="graphic_reference">Adapted from: Rick ME. Diagnosis and management of von Willebrand's syndrome. Med Clin North Am 1994; 78:609. Copyright 1994 WB Saunders.</div><div id="graphicVersion">Graphic 75956 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
